Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.
NOVT · Novanta Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Novanta reported third-quarter GAAP revenue of $305 million, up 23%, while Adjusted EBITDA rose 38% to $80 million. It expects full-year 2026 GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Novanta Inc. completed its acquisition of Runway Buyer, LLC on July 23, 2026 for approximately $1.2 billion in cash, plus a $250.0 million milestone payment due on or before January 8, 2027. Runway Buyer reported 2025 revenue of $136,120,000 and net income of 11,462,563.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted EPS non-GAAP | $1.05 | Third quarter 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Diluted EPS $0.05
+$1 Total non-GAAP adjustments
= Adjusted Diluted EPS $1.05
|
|||
| Adjusted EBITDA non-GAAP | $80.3M | Third quarter 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 26% | Third quarter 2026 | — |
|
|
|||
| Adjusted Operating Income non-GAAP | $65.1M | Third quarter 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Operating Income 13.91M
+21.41M Amortization of intangible assets
+3.87M Restructuring costs
+19.22M Acquisition and related costs
+800K Inventory acquisition fair value adjustments
+3.69M Planning and design phase of the financial and operation system implementation
+921K Operational transformation costs
+1.05M EU medical device regulation charges
+221K Costs incurred for insurance recovery claim
= Adjusted Operating Income 65.08M
|
|||
| backlog | $543M | Third quarter 2026 | — |
| Net Debt (Non-GAAP) non-GAAP | $689.42M | October 2, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Total Debt (GAAP) 829.83M
+8.81M Plus: Deferred financing costs
-149.22M Less: Cash and cash equivalents
= Net Debt (Non-GAAP) 689.42M
|
|||
| Organic Revenue Growth non-GAAP | 9.9% | Third quarter 2026 | — |
|
|
|||
| Adjusted Gross Margin non-GAAP | 47% | Q2 2026 | — |
| Adjusted Gross Profit (Non-GAAP) non-GAAP | $125.1M | Three Months Ended July 3, 2026 | — |
| Adjusted Gross Profit Margin (Non-GAAP) non-GAAP | 47.1% | Three Months Ended July 3, 2026 | — |
| Adjusted Net Income (Non-GAAP) non-GAAP | $36.53M | Three Months Ended July 3, 2026 | — |
| Adjusted Operating Margin (Non-GAAP) non-GAAP | 17.9% | Three Months Ended July 3, 2026 | — |
| Free Cash Flow (Non-GAAP) non-GAAP | $57.47M | Three Months Ended July 3, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net Cash Provided by Operating Activities 64.93M
-7.47M Purchases of property, plant and equipment
= Free Cash Flow (Non-GAAP) 57.47M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Scientific & Technical Instruments — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NOVT
this stock
Novanta Inc
|
$4.46B | -0.9% | +35.5% | 89.3 | 13.9% |
|
GRMN
Garmin Ltd
|
$53.86B | +37.8% | +15.1% | 26.9 | 1.6% |
|
KEYS
Keysight Technologies, Inc.
|
$48.74B | +40.9% | +8.0% | 39.2 | 1.3% |
|
COHR
Coherent Corp.
|
$41.92B | +15.3% | +19.2% | 44.1 | 5.1% |
|
TDY
Teledyne Technologies Inc
|
$28.90B | +22.9% | -4.6% | 28.7 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 17
Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NOVT | -4.4% | -15.8% | -26.0% | -19.1% | -0.9% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -0.5% | -10.2% | -22.5% | -15.7% | -8.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.